arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

QIAGEN N.V.

QGEN
$42.27 ▲ +0.55 (+1.32%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
19 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
74
Health
Good
Bullish
auto_awesome

Analytical Summary

QIAGEN N.V. shows strong fundamentals with top-quartile Profit Margin (%) and Operating Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $9.2B
Dividend Yield 0.59%
Revenue Growth 5.7%
Op. Margin 22.3%
ROIC 7.4%
FCF / Share $2.09
Trailing P/E 21.6x
Price / Book 2.4x
FCF Yield 4.9%
Debt / Equity 0.44
info Valuation on last close. End-of-day price, Aug 7, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.09B
↑ +5.7%
Net Income Profit after all expenses
$424.88M
↑ +408.3%
Operating Margin Operating profit as % of sales
22.3%
↑ +351.3% 78th
FCF / Share Free cash flow per share
$2.09
↓ -8.3%
Long-Term Debt Long-term obligations
$1.65B
↑ +18.9%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
81
Returns
71
Financial Health
71
Cash Quality
68

Dividend History

Dividend / share · sourced from SEC filings
$0.25 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 19 quarters